Pyrazole scaffold‐based derivatives: A glimpse of α‐glucosidase inhibitory activity, SAR, and route of synthesis

The α‐glucosidase is a validated target to develop drugs for treating type 2 diabetes mellitus. The existing α‐glucosidase inhibitors have certain shortcomings related to side effects and route of synthesis. Accordingly, it is inevitable to develop new chemical templates as α‐glucosidase inhibitors. Pyrazole derivatives have a special place in medicinal chemistry because of various biological activities. Recently, pyrazole‐based heterocyclic compounds have emerged as a promising scaffold to develop α‐glucosidase inhibitors. This study focuses on the recently reported pyrazole‐based α‐glucosidase inhibitors, including their biological activity (in vivo, in vitro, and in silico), structure–activity relationship, and ways of synthesis. The literature revealed the development of several promising pyrazole‐based α‐glucosidase inhibitors and new synthetic routes for their preparation. The encouraging α‐glucosidase inhibitory results of the pyrazole‐based heterocyclic compounds make them an attractive target for further research. The authors also foresee the arrival of the pyrazole‐based α‐glucosidase inhibitors in clinical practice. Pyrazole‐based heterocyclic compounds have emerged as a promising scaffold to develop α‐glucosidase inhibitors, for example, for the treatment of type 2 diabetes mellitus. This study focuses on the recently reported pyrazole‐based α‐glucosidase inhibitors, including their biological activity (in vivo, in vitro, and in silico), structure–activity relationship, and ways of synthesis.